Apply Now for AACR Cancer Research Awards

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

The American Association for Cancer Research (AACR) has announced the availability of its four annual research awards. The Gertrude Elion award, provided through an educational grant from Glaxo Wellcome Oncology, is open to nontenured cancer researchers in clinical, basic, or translational research in the United States and Canada.

The American Association for Cancer Research (AACR) has announcedthe availability of its four annual research awards. The GertrudeElion award, provided through an educational grant from GlaxoWellcome Oncology, is open to nontenured cancer researchers inclinical, basic, or translational research in the United Statesand Canada.

The two 1997 Research Fellowships in Clinical/Translational Research,sponsored by Amgen, Inc. and Bristol-Myers Squibb Oncology, andthe 1997 Research Fellowship in Basic Research will go to scientistswho have been postdoctoral or clinical fellows at an academicinstitution in the United States or Canada for at least, but notmore than, 5 years.

A completed application form and sponsorship by an AACR memberare required for each award. The application deadline is February14, 1997. For application forms, contact Jenny Anne Horst-Martzby phone: 215-440-9300; fax: 215-440-9313; or e-mail: aacr@aol.com.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content